Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
The risks and benefits of early immunosuppression and biological therapy
Bruce E. Sands
Brain-Body Center
Friedman Brain Institute
Graduate School of Biomedical Sciences
Icahn School of Medicine at Mount Sinai
Medicine
Medicine - Gastroenterology
Research output
:
Contribution to journal
›
Article
›
peer-review
7
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The risks and benefits of early immunosuppression and biological therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Early Intervention
100%
Immunosuppressive Therapy
100%
Biological Therapy
100%
Improved Outcomes
33%
Early Treatment
33%
Risk Stratification
33%
Inflammatory Bowel Disease
33%
Crohn's Colitis
33%
Early Disease
33%
Disease Course
33%
Optimal Strategy
33%
Inflammatory Process
33%
Heterogeneous Conditions
33%
Disease Behavior
33%
Window of Opportunity
33%
Complicated Disease
33%
Potential Window
33%
Immune Suppression Therapy
33%
Medicine and Dentistry
Early Intervention
100%
Immunosuppressive Treatment
100%
Biological Therapy
100%
Diseases
100%
Risk Stratification
33%
Ulcerative Colitis
33%
Serositis
33%
Crohn's Disease
33%
Inflammatory Bowel Disease
33%
Immunology and Microbiology
Inflammatory Bowel Disease
100%
Immunosuppression
100%
Crohn's Disease
100%
Ulcerative Colitis
100%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
100%
Inflammation
33%
Inflammatory Bowel Disease
33%
Ulcerative Colitis
33%
Crohn's Disease
33%